Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REC-01 MSC transplantation in pediatric hypophosphatasia (phase I/IIa FIH)
jRCT2063210019Phase 1Suspended
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dutogliptin in hypophosphatasia (HPP), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety (adverse events and malfunctions). Started Jun 2021; status: suspended.
02
Drugs
dutogliptin
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on jRCT2063210019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063210019.